Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Elite Pharmaceuticals (AMEX:ELI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Msgs
Location
165 Ludlow Avenue
Northvale, NJ 07647
Phone: (201) 750-2646
Fax: (201) 750-2755
Email: elitelabs@aol.com
Employees (last reported count): 11
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 55%
·Institutional: 1% (2% of float)
(4 institutions)
·Net Inst. Buying: 23.0K shares (+26.45%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Elite Pharmaceuticals, Inc. (EPI) is the holding company of Elite Laboratories, Inc. (ELI), which primarily is engaged in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. ELI has concentrated on developing orally administered controlled release products. EPI has undertaken and completed several contract product development projects for clients, including Celgene, Novo Nordisk and SmithKline Beecham. The Company has developed products incorporating cardiovasculars, anti-inflammatory agents, antidiabetic, cough and cold preparations, bronchodilators, analgesics, and anti-infectives. The Company's products include Nifelite (Nifedipine), Diltilite CD (Diltiazem), Diltilite SR, Ketolite CR (Ketoprofen), Verelite CR (Verapamil), Glucolite CR (Glipizide), and Diclofelite CR (Diclofenac). Several of these oral controlled release products are available for license worldwide.
More from Market Guide: Expanded Business Description

Financial Summary
ELI engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Elite also conducts research and development projects sponsored by other pharmaceutical companies. For the three months ended 6/30/01, revenues totaled $76 thousand, up from $0. Net loss fell 24% to $447 thousand. Results reflect a $76 thousand product formulation fee, partially offset by a $61 thousand equity loss in joint venture.
More from Market Guide: Significant Developments

Officers
FY2001 Pay

Atul Mehta, Ph.D., 52
Pres, CEO, Director
$297K
Mark Gittelman, 41
Sec., Treasurer
--  
Dollar amounts are as of 31-Mar-2001 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:ELIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 15-Mar-2001
$4.65 
Recent Price$7.90 
52-Week High
on 3-Oct-2000
$13.25 
Daily Volume (3-month avg)14.5K
Daily Volume (10-day avg)11.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change+3.6%
52-Week Change
relative to S&P500
+39.0%
Share-Related Items
Market Capitalization$74.5M
Shares Outstanding9.43M
Float4.20M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)-$0.33 
Earnings (ttm)-$1.54 
Earnings (mrq)-$0.05 
Sales (ttm)$0.02 
Cash (mrq)$0.74 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)428.12 
Income Statements
Sales (ttm)$171.0K
EBITDA (ttm)-$1.99M
Income available to common (ttm)-$13.8M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsMar 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-98.02%
Return on Equity (ttm)-1037.14%
Financial Strength
Current Ratio (mrq)12.08 
Debt/Equity (mrq)0.33 
Total Cash (mrq)$7.03M
Short Interest
As of 8-Aug-2001
Shares Short133.0K
Percent of Float3.2%
Shares Short
(Prior Month)
133.0K
Short Ratio12.09 
Daily Volume11.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.